3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Trastuzumab
350
Paclitaxel
334
Cyclophosphamide
315
Docetaxel
291
Capecitabine
181
Doxorubicin
180
Letrozole
166
Tamoxifen
145
Bevacizumab
124
Fulvestrant
118
Carboplatin
118
exemestane
111
Lapatinib
111
Anastrozole
111
Radiotherapy
105
Epirubicin
104
Gemcitabine
97
palbociclib
84
Exercise
78
Vinorelbine
77
Fluorouracil
77
Surveys and Questionnaires
71
pertuzumab
67
Filgrastim
64
Albumin-Bound Paclitaxel
64
eribulin
55
Magnetic Resonance Spectroscopy
55
Everolimus
52
Blood Specimen Collection
51
Zoledronic Acid
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts